Skip to main content
ABINGDON HEALTH PLC logo

ABINGDON HEALTH PLC — Investor Relations & Filings

Ticker · ABDX ISIN · GB00BLF79J41 LEI · 213800XFI4WV3FBILO20 IL Manufacturing
Open in API
Filings indexed 261 across all filing types
Latest filing 2025-01-27 Regulatory Filings
Country GB United Kingdom
Listing IL ABDX

About ABINGDON HEALTH PLC

https://www.abingdonhealth.com/

Abingdon Health PLC is a contract development and manufacturing organization (CDMO) that specializes in lateral flow assays, also known as rapid tests. The company provides a comprehensive, fully integrated service to a global customer base, supporting diagnostic projects from initial concept and development through to high-volume automated manufacturing and regulatory support. Its services cater to a wide range of sectors, including clinical, animal health, environmental, and plant health. Abingdon Health also develops and manufactures lateral flow readers and smartphone reader applications, which complement its assay services by enabling digital data capture and analysis.

Recent filings

Filing Released Lang Actions
Funding award to develop test for malaria parasite
Regulatory Filings Classification · 98% confidence The document is clearly identified as an RNS announcement by the header 'RNS Number : 6716U' and the closing statement referencing RNS as the news service of the London Stock Exchange, approved by the FCA. The content details a specific corporate event: the awarding of a funding grant for developing a malaria diagnostic test. This type of immediate, material, non-periodic corporate news release that doesn't fit into specific categories like 10-K, ER, or DIV is best classified as a general Regulatory Filing (RNS), as it is disseminated via the official regulatory news service.
2025-01-27 English
CS (Lifesciences) Ltd contract win
Regulatory Filings Classification · 100% confidence The document starts with an 'RNS Number' and a date, indicating it is a regulatory announcement. The content describes a contract win by a subsidiary of Abingdon Health plc, detailing the value and nature of the contract. This type of announcement, which is a material, non-financial update released via the Regulatory News Service (RNS), fits best under the general 'Regulatory Filings' category, as it is not a specific financial report (like 10-K or ER), a management change (MANG), or a director's dealing (DIRS). Since it is a standard, brief announcement distributed through the RNS system, RNS is the most appropriate classification.
2025-01-08 English
Directorate Change
Board/Management Information Classification · 100% confidence The document is identified by the header 'RNS Number : 6515Q' and concludes with standard disclaimers from RNS, the news service of the London Stock Exchange, which acts as a Primary Information Provider. The content explicitly announces the 'Appointment of Chief Financial Officer' and details the new director's background and required AIM Rule disclosures. This type of announcement, concerning changes in senior management, directly corresponds to the definition of Board/Management Information (MANG). Although it is distributed via RNS, the core subject matter is management change, making MANG the most specific classification.
2024-12-19 English
Abingdon Analytical Laboratory opens at Doncaster
Regulatory Filings Classification · 100% confidence The document begins with 'RNS Number : 3781Q' and contains standard boilerplate language associated with regulatory news services, specifically mentioning 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content is a brief announcement regarding the opening of a new analytical laboratory and related investment, which is a corporate update that doesn't fit the specific definitions of 10-K, ER, IR, or DIV. Since it is a general regulatory announcement distributed via the RNS system and does not clearly map to a more specific category like DIRS, MANG, or CAP, the most appropriate classification is the general regulatory filing category.
2024-12-17 English
Contract win: sexually transmitted disease tests
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and explicitly states it contains 'INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF REGULATION (EU) NO 596/2014 WHICH IS PART OF UK LAW'. The content announces a significant contract win ('Contract win: sexually transmitted disease tests') and provides details about the agreement, financial value (up to US$2 million), and regulatory steps. The document concludes with standard RNS disclaimers and contact information for RNS/LSE. This format is characteristic of a general regulatory announcement disseminated via the London Stock Exchange's Regulatory News Service (RNS). Since the content is a specific business update (contract win) and not a standard periodic report (like 10-K or IR), nor a specific announcement like a dividend (DIV) or director dealing (DIRS), the most appropriate classification is the general regulatory filing category, RNS.
2024-12-17 English
Group of companies' accounts made up to 2024-06-30
Regulatory Filings
2024-12-06 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.